ClinicalTrials.gg
CompletedNCT04037345Updated Feb 24, 2021

Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis

A Phase 1 interventional study of SMUP-IA-01(low-dose) and SMUP-IA-01(mid-dose) in Knee Osteoarthritis, sponsored by Medipost Co Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by Medipost Co Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Enrollment
81st of 85
12 · median 124
Started
2019
with 4 others
Phase 1
3 of 96
1 open now
Registered
55th of 96
by date
Lead sponsor
4 of 96
Medipost Co Ltd.

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 81st largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2019, is one of 3 in phase 1, and was the 55th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is performed with patients with knee osteoarthritis who were radiologically diagnosed with Kellgren-Lawrence (K\&L) grade 2 or 3. Subjects who voluntarily signed consent form and met inclusion/exclusion criteria, were evaluated eligible and participated in this trial. Investigator selected knee to be evaluated (right or left) and administered investigational product to selected knee on Day 1.

A total of 3 or 6 subjects will be enrolled in low-dose or mid-dose group each, and 6 subjects will be enrolled in high-dose group. The study used a dose escalation scheme (from low-dose to high-dose) to determine the maximum tolerated dose (MTD).

Read the detailed description

All subjects in each dose-group will visit 1 month* (visit 5, 1 month±5 days) after administration of investigational product to evaluate dose limit toxicity (DLT) and determine whether to drop or proceed to next dose level.

Total 5 visit (1week, 1 month, 2 months, 3 months, 6 months) until 6 months after administration of investigational product is planned to assess safety through vial sign, laboratory tests, and exploratory efficacy of IP will be assessed through Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS) and International Knee Documentation Committee (IKDC) subjective knee evaluation.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • human umbilical cord blood derived mesenchymal stem cells
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female over 19 years of age
  2. Subject with knee osteoarthritis (OA) and were diagnosed K\&L grade 2 or 3 in radioactive examination at time of screening
  3. Subject with more than 40mm joint pain on the 100-mm VAS, at the time of screening
  4. Subject who were diagnosed as knee osteoarthritis by American College of Rheumatology (ACR) guideline criteria, at the time of screening
  5. Subject with (BMI) ≤35 kg/m2 at the time of screening
  6. Subject with ligament instability ≤Grade II (grade o: no ligament instability, grade I: 0 \~ 5㎜, grade Ⅱ: 5 \~ 10 ㎜, grade Ⅲ: > 10 ㎜) at the time of screening
  7. Subject who agree to maintain during study period
  8. Subject who voluntarily agreed to participate in the study, and signed

Exclusion criteria

Exclusion Criteria:

  1. Subject with myocardial infarction, congestive heart failure, and other severe heart disease or hypertension (or medical history of hypertension) that are not controlled below 140/90mmHg even with treatment with more than three(3) antihypertensive drugs
  2. Subject with serious medical conditions other than cardiovascular disease
  3. Subject with, or with a medical history of auto-immune diseases
  4. Subject with an infection that requires parenteral antibiotic administration.
  5. Subject with a medical history of mental disorder or epilepsy
  6. Subject with chronic inflammatory joint diseases such as rheumatoid arthritis (e.g., osteoarthritis with infectious joint disease, gouty arthritis, and osteoarthritis)
  7. Subject who had surgery or radiation therapy on knee joint area, or have not recovered from side effects of knee joint surgery within 12 weeks before screening
  8. Subject who are pregnant or lactating
  9. Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day
  10. Subject who were diagnosed with cancer within 5 years before screening
  11. Subject who particiapted in another clinical trial within 4 weeks before screening of this clinical trial
  12. Subject who were administered with immunosuppressnats such as cyclosporin A or azathioprine within 6 weeks before screening
  13. Subject who had intra-articular administration such as sodium hyaluronate injections within 6 month before screening
  14. Subject who are suffering from skin disease or considered inappropriate for injection in the injection site
  15. Subject who has history of allergic response to hyaluronate injections or DMSO (cryopreservative) or Gentamicin (antibiotics)
  16. Subject who are consiered inappropriate for MRI assessment with Tesla higher than 3.0
  17. Subject with medical history of cell therapy product administration or are scheduled to administer other cell therapy product
  18. Subject who principal investigator (PI) considers inappropriate to participate in the study due to any reasons other than those listed above
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SMUP-IA-01(low-dose)

    A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10\^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(low-dose)

  • Experimental
    SMUP-IA-01(mid-dose)

    A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10\^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(mid-dose)

  • Experimental
    SMUP-IA-01(high-dose)

    A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(high-dose)

Interventions

  • BiologicalSMUP-IA-01(low-dose)

    A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

    Also known as: Human umbilical cord blood-derived mesenchymal stem cells

  • BiologicalSMUP-IA-01(mid-dose)

    A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

    Also known as: Human umbilical cord blood-derived mesenchymal stem cells

  • BiologicalSMUP-IA-01(high-dose)

    A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)

    Also known as: Human umbilical cord blood-derived mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment

    Change of total scorein WOMAC compared to baseline at 6 months after treatment. WOMAC consists of three subscales: pain, stiffness, and physical function, and is performed on baseline (visit 2) and final (Visit 8) visits. Total of 24 questions are evaluated with 5 questions for pain, 2 questions for stiffness, and 17 questions for physical function. Each question is scored between 0 point (no symptom) \~ 4 points (severe symptoms) scale, and the total score is between 0 point (no symptoms) \~ 96 points (higher score representing worse symptoms).

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment

    The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).

    Time frame: Baseline, Month 6

  2. Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline

    The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 6

  3. Change of score in IKDC(International Knee Documentation Committee)compared to baseline

    Change of score in IKDC compared to baseline. IKDC subjective knee evaluation consists of three categories: symptoms, sports activities, and functions. For each category, there are 7 questions for symptoms, 2 questions for sports activities, and 2 questions for functions, a total of 11 questions for evaluation. The scores for each category are summed up and divided into 87, which is the maximum score possible, and then is evaluated by converting it into a scale of 100 points. Higher score indicates better function and less symptoms for the knee.

    Time frame: Baseline, Month 1, Month 2, Month 3, Month 6

  4. Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment

    For structural and tissue evaluation of knee, MRI image of detailed knee parts are graded from min. 0 to max. 6. Lower number indicate normal status

    Time frame: Baseline, Month 6

  5. Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment

    The K \& L grade is 0 to 4 Grade, which means that the higher the grade, the greater the joint damage and the stenosis of the joint.

    Time frame: Baseline, Month 3, Month 6

  6. Change in joint space width compared to the baseline at 3 months and 6 months after treatment

    Evaluation of disease progression in target knee as ascertained by change from baseline in joint space width (JSW) determined using radiography

    Time frame: Baseline, Month 3, Month 6

  7. Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment

    The degree of deformation of the lower half of the body is measured by measuring the angles of the mechanical axis and the anatomical axis with respect to the vertical axis. Mechanical axis: A line connecting the femoral head center point and the ankle joint center point. Anatomical axis: The middaphyseal line of the femur and tibia.

    Time frame: Baseline, Month 3, Month 6

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Jongno-gu 03080, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Nov 2020, 13 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 13 months is close to that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 30, 2019
StartActual
Oct 7, 2019
Primary completionActual
Nov 12, 2020
CompletionActual
Nov 12, 2020
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04037345
Lead sponsor
Medipost Co Ltd.
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Oct 7, 2019
Primary completion
Nov 12, 2020
Completion
Nov 12, 2020
Last update
Feb 24, 2021

Study contacts

Myungchul Lee, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion